Currently out of the existing stock ratings of Pasha Sarraf, 4 are a HOLD (33.33%), 7 are a BUY (58.33%), 1 are a SELL (8.33%).

Pasha Sarraf

Work Performance Price Targets & Ratings Chart

Analyst Pasha Sarraf, carries an average stock price target met ratio of 80% that have a potential upside of 64.11% achieved within 631 days. Previously, Pasha Sarraf worked at LEERINK.

Pasha Sarraf’s has documented 23 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ACRS, Aclaris Therapeutics at 03-Mar-2021.

Wall Street Analyst Pasha Sarraf

Analyst best performing recommendations are on ACRS (ACLARIS THERAPEUTICS).
The best stock recommendation documented was for ACRS (ACLARIS THERAPEUTICS) at 3/4/2021. The price target of $26 was fulfilled within 15 days with a profit of $4.86 (22.99%) receiving and performance score of 15.33.

Average potential price target upside

ACRS Aclaris Therapeutics PRVB Provention Bio VKTX Viking Therapeutics CBAY Cymabay Therapeu ICPT Intercept Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

3 months 15 days ago
(24-Jun-2025)

0/5 (0%)

$34.34 (396.54%)

Buy

5 months 1 days ago
(08-May-2025)

0/7 (0%)

$23.92 (169.89%)

Hold

$2

$0.14 (7.53%)

$2

7 months 13 days ago
(26-Feb-2025)

2/4 (50%)

$0.05 (2.56%)

271

Buy

$8

$6.14 (330.11%)

10 months 21 days ago
(18-Nov-2024)

0/3 (0%)

$3.41 (74.29%)

Buy

$7

$5.14 (276.34%)

10 months 21 days ago
(18-Nov-2024)

1/4 (25%)

$2.41 (52.51%)

315

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Pasha Sarraf?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?